title: Effect of rosiglitazone on rabbit model of myocardial ischemia-reperfusion injury.
abstract: OBJECTIVE
  To explore mechanism and protective effect of rosiglitazone on myocardial ischemia reperfusion (I/R) injury.
  
  
  METHODS
  A total of 48 male Japanese white big-ear rabbits were randomly divided into control group (A), I/R group (B), low dose of rosiglitazone group (C), high dose of rosiglitazone group (D). Plasma concentration of and also reduced the concentration of plasma serum creatine kinase (CK), CK-MB, high-sensitivity C-reactive protein (hsCRP), ultra-superoxide dismutase (SOD), malondialdehyde (MDA), lactic acid glutathione skin peroxidase (GSH-PX), nitric oxide (NO) and endothelin (ET) were measured 1 h later after I/R. Twenty-four hours after I/R the hearts were harvested for pathological and ultrastructural analysis. Area of myocardial infarction were tested.
  
  
  RESULTS
  Plasma concentration of CK, CK-MB, hsCRP, NO, MDA and ET were decreased in C, D group compared with group B. Plasma concentration of T-SOD and GSH-Px were increased significantly in C, D group compared with group B. Compared with group B, pathological and ultrastructural changes in C and D group were slightly. There was significant difference in myocardial infarction area between group C, D and group B (P<0.05). Myocardial infarction area and arrhythmia rate were lower in group C, D compare with group B.
  
  
  CONCLUSIONS
  Rosiglitazone may protect myocardium from I/R injury by enhancing T-SOD and GSH-Px concentration, inhibit inflammatory reaction, and improve endothelial function.
authors: Liaoning Medical University, Jinzhou 121000, China.
authors: Xia-Qing
authors: XQ
authors: Gao
authors: Hua-Wei
authors: HW
authors: Li
authors: Xue
authors: X
authors: Ling
authors: Ya-Hui
authors: YH
authors: Qiu
authors: Yue
authors: Y
authors: Gao
authors: Yang
authors: Y
authors: Zhang
mesh_terms: D000818:Animals; D002097:C-Reactive Protein / Q000378:metabolism; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D004195:Disease Models, Animal; D016232:Endothelins / Q000097:blood; D005979:Glutathione Peroxidase / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D015428:Myocardial Reperfusion Injury / Q000097:blood / Q000517:prevention & control*; D009206:Myocardium / Q000648:ultrastructure*; D009569:Nitric Oxide / Q000097:blood; D011817:Rabbits; D000077154:Rosiglitazone; D013482:Superoxide Dismutase / Q000097:blood; D045162:Thiazolidinediones / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D016232:Endothelins; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D009569:Nitric Oxide; D008315:Malondialdehyde; D002097:C-Reactive Protein; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form